Chiara Borsari - Concepedia

Author

Chiara Borsari

University of Modena and Reggio Emilia ORCID

Also Known As

Chiara Borsari

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

University of Modena and Reggio Emilia University of Basel Fraunhofer Institute for Molecular Biology and Applied Ecology i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto PIQUR Therapeutics (Switzerland)

About

Chiara Borsari is an author at University of Modena and Reggio Emilia specializing in medicine, natural sciences, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	11	399
2	Natural Sciences	9	9	210
3	Biochemistry	9	9	216
4	Chemical Biology	3	3	45
5	Cell Biology	1	1	51

Chiara Borsari

Publications

933

Citations

H-Index

Page 1

	Year	Citations
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology Florent Beaufils, Nataša Cmiljanović, Vladimir Cmiljanović, Journal of Medicinal Chemistry Chemoprevention StrategyImmunologyClinical CandidatePi3k/mtor InhibitorPharmacotherapy	2017	132
Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders Denise Rageot, Thomas Bohnacker, Anna Melone, Journal of Medicinal Chemistry	2018	83
Chroman-4-One Derivatives Targeting Pteridine Reductase 1 and Showing Anti-Parasitic Activity F. Di Pisa, Giacomo Landi, Lucia Dello Iacono, Molecules	2017	64
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs Chiara Borsari, Rosaria Luciani, Cecilia Pozzi, Journal of Medicinal Chemistry	2016	55
(<i>S</i>)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase Denise Rageot, Thomas Bohnacker, Erhan Keleş, Journal of Medicinal Chemistry Compound 6Brain PenetrationCellular PharmacologyPharmacotherapyPharmaceutical Chemistry	2019	54
Disease-related mutations in PI3Kγ disrupt regulatory C-terminal dynamics and reveal a path to selective inhibitors Manoj K Rathinaswamy, Zied Gaieb, Kaelin D. Fleming, eLife Molecular RegulationImmunologySelective InhibitorsInnate ImmunityCancer Biology	2021	51
Covalent Proximity Scanning of a Distal Cysteine to Target PI3Kα Chiara Borsari, Erhan Keleş, Jacob A. McPhail, Journal of the American Chemical Society	2022	51
A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor Chiara Borsari, Denise Rageot, Alix Dall’Asen, Journal of Medicinal Chemistry	2019	40
Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl–Pyrimidine Moiety Chiara Borsari, Denise Rageot, Florent Beaufils, ACS Medicinal Chemistry Letters	2019	39
Crassiflorone derivatives that inhibit Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase ( Tb GAPDH) and Trypanosoma cruzi trypanothione reductase ( Tc TR) and display trypanocidal activity Elisa Uliassi, Giulia Fiorani, R. Luise Krauth‐Siegel, European Journal of Medicinal Chemistry Tc TrTb GapdhBiochemistryAntiparasitic AgentMedicine	2017	31

Page 1